These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 18506391)

  • 21. Dopaminergic substitution in Parkinson's disease.
    Müller T
    Expert Opin Pharmacother; 2002 Oct; 3(10):1393-403. PubMed ID: 12387685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Movement chunking during sequence learning is a dopamine-dependant process: a study conducted in Parkinson's disease.
    Tremblay PL; Bedard MA; Langlois D; Blanchet PJ; Lemay M; Parent M
    Exp Brain Res; 2010 Sep; 205(3):375-85. PubMed ID: 20680249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Working memory functioning in medicated Parkinson's disease patients and the effect of withdrawal of dopaminergic medication.
    Fournet N; Moreaud O; Roulin JL; Naegele B; Pellat J
    Neuropsychology; 2000 Apr; 14(2):247-53. PubMed ID: 10791864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dopamine replacement therapy and deep brain stimulation of the subthalamic nuclei induce modulation of emotional processes at different spatial frequencies in Parkinson's disease.
    Mermillod M; Mondillon L; Rieu I; Devaux D; Chambres P; Auxiette C; Dalens H; Coulangeon LM; Jalenques I; Durif F
    J Parkinsons Dis; 2014; 4(1):97-110. PubMed ID: 24496100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of dopamine and cognitive impairment on neural reactivity to facial emotion in Parkinson's disease.
    Dan R; Růžička F; Bezdicek O; Roth J; Růžička E; Vymazal J; Goelman G; Jech R
    Eur Neuropsychopharmacol; 2019 Nov; 29(11):1258-1272. PubMed ID: 31607424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Basal ganglia, dopamine and temporal processing: performance on three timing tasks on and off medication in Parkinson's disease.
    Jones CR; Malone TJ; Dirnberger G; Edwards M; Jahanshahi M
    Brain Cogn; 2008 Oct; 68(1):30-41. PubMed ID: 18378374
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Different effects of levodopa and subthalamic stimulation on emotional conflict in Parkinson's disease.
    Martínez-Fernández R; Kibleur A; Chabardès S; Fraix V; Castrioto A; Lhommée E; Moro E; Lescoules L; Pelissier P; David O; Krack P
    Hum Brain Mapp; 2018 Dec; 39(12):5014-5027. PubMed ID: 30259598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deep brain stimulation of the subthalamic nucleus enhances emotional processing in Parkinson disease.
    Schneider F; Habel U; Volkmann J; Regel S; Kornischka J; Sturm V; Freund HJ
    Arch Gen Psychiatry; 2003 Mar; 60(3):296-302. PubMed ID: 12622663
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patients with Parkinson's disease display a dopamine therapy related negative bias and an enlarged range in emotional responses to facial emotional stimuli.
    Lundqvist D; Svärd J; Michelgård Palmquist Å; Fischer H; Svenningsson P
    Neuropsychology; 2017 Sep; 31(6):605-612. PubMed ID: 28581310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopamine is associated with prioritization of reward-associated memories in Parkinson's disease.
    Sharp ME; Duncan K; Foerde K; Shohamy D
    Brain; 2020 Aug; 143(8):2519-2531. PubMed ID: 32844197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Processing of emotional information in the human subthalamic nucleus.
    Buot A; Welter ML; Karachi C; Pochon JB; Bardinet E; Yelnik J; Mallet L
    J Neurol Neurosurg Psychiatry; 2013 Dec; 84(12):1331-8. PubMed ID: 23100448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dopamine modulates the response of the human amygdala: a study in Parkinson's disease.
    Tessitore A; Hariri AR; Fera F; Smith WG; Chase TN; Hyde TM; Weinberger DR; Mattay VS
    J Neurosci; 2002 Oct; 22(20):9099-103. PubMed ID: 12388617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Are dopaminergic pathways involved in theory of mind? A study in Parkinson's disease.
    Péron J; Vicente S; Leray E; Drapier S; Drapier D; Cohen R; Biseul I; Rouaud T; Le Jeune F; Sauleau P; Vérin M
    Neuropsychologia; 2009 Jan; 47(2):406-14. PubMed ID: 18845171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dopaminergic medication counteracts conflict adaptation in patients with Parkinson's disease.
    Duthoo W; Braem S; Houtman F; Schouppe N; Santens P; Notebaert W
    Neuropsychology; 2013 Sep; 27(5):556-61. PubMed ID: 23815093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of aging, Parkinson's disease, and dopaminergic medication on response selection and control.
    Willemssen R; Falkenstein M; Schwarz M; Müller T; Beste C
    Neurobiol Aging; 2011 Feb; 32(2):327-35. PubMed ID: 19269061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rhythmic movement in Parkinson's disease: effects of visual feedback and medication state.
    Levy-Tzedek S; Krebs HI; Arle JE; Shils JL; Poizner H
    Exp Brain Res; 2011 Jun; 211(2):277-86. PubMed ID: 21526337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emotional valence may influence memory performance for visual artworks in Parkinson's disease.
    Ciccarelli N; Di Tella S; Lo Monaco MR; Carfì A; Serafini E; Delle Donne V; Silveri MC
    Neurol Sci; 2019 Oct; 40(10):2175-2178. PubMed ID: 31144156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson's disease.
    Eusebio A; Witjas T; Cohen J; Fluchère F; Jouve E; Régis J; Azulay JP
    J Neurol Neurosurg Psychiatry; 2013 Aug; 84(8):868-74. PubMed ID: 23447648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The function of dopaminergic neural signal transmission in auditory pulse perception: evidence from dopaminergic treatment in Parkinson's patients.
    Geiser E; Kaelin-Lang A
    Behav Brain Res; 2011 Nov; 225(1):270-5. PubMed ID: 21787806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dopamine improves exploration after expectancy violations and induces psychotic-like experiences in patients with Parkinson's disease.
    Polner B; Moustafa AA; Nagy H; Takáts A; Győrfi O; Kéri S
    Neurosci Lett; 2016 Mar; 616():132-7. PubMed ID: 26820375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.